NTRR NEUTRA CORP.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1512886 · Fiscal year ends 01/31
Financial factors as of 2023-10-31 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.7%
TTM net income YoY-2.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-1,457.1%
Net margin-2,723.6%
FCF margin—
EBITDA margin-1,103.4%
Returns
ROE—
ROA-758.7%
ROIC (approx.)—
Asset turnover0.28x
Leverage & solvency
Liabilities / assets3,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage-14.07x
Cash quality & payout
Operating cash flow / net income0.02x
Accruals ratio-743.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q32023-10-31 | 2024Q22023-07-31 | 2024Q12023-04-30 | 2023Q4*2023-01-31 | 2023Q32022-10-31 | 2023Q22022-07-31 | 2023Q12022-04-30 | 2022Q4*2022-01-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1,311 | $4,325 | $5,842 | $5,919 | $23,383 | $29,032 | $9,662 | $38,383 |
| Cost of revenue | $722 | $2,643 | $3,038 | $2,965 | $12,708 | $12,479 | $4,538 | $9,639 |
| Gross profit | $589 | $1,682 | $2,804 | $2,954 | $10,675 | $16,553 | $5,124 | $28,744 |
| SG&A expense | $43,487 | $57,817 | $50,781 | $41,016 | $46,439 | $65,018 | $75,501 | $155,080 |
| Operating income | -$52,728 | -$71,769 | -$71,208 | -$57,789 | -$66,074 | -$82,350 | -$91,462 | -$160,668 |
| Interest expense | $2,258 | $29 | $199 | $15,535 | $15,718 | $15,076 | $15,734 | $15,105 |
| Pretax income | -$54,986 | -$71,798 | -$71,407 | -$271,480 | -$81,792 | -$97,426 | -$107,196 | — |
| Income tax | $0 | $49 | $589 | — | — | — | — | — |
| Net income | -$54,986 | -$71,847 | -$71,996 | -$275,003 | -$81,792 | -$97,426 | -$107,196 | -$175,773 |
| EBITDA | -$43,677 | -$58,730 | -$51,482 | -$38,062 | -$46,348 | -$62,623 | -$71,736 | -$140,941 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $692 | $1,134 | $3,138 | $1,969 | $456 | $26,325 | $15,188 | $1,056 |
| Receivables | $98 | — | — | — | — | — | — | — |
| Inventory | $18,610 | $19,213 | $21,332 | $23,846 | $26,810 | $25,108 | $21,991 | — |
| Current assets | $19,400 | $20,347 | $24,470 | $25,815 | $28,876 | $53,043 | $38,789 | $2,666 |
| PP&E, net | $7,544 | $16,595 | $29,634 | $49,360 | $69,087 | $88,813 | $108,540 | $128,266 |
| Total assets | $26,944 | $36,942 | $54,104 | $75,175 | $97,963 | $141,856 | $147,329 | $130,932 |
| Current liabilities | $908,828 | $863,840 | $809,155 | $759,639 | $1.25M | $1.21M | $1.21M | $1.15M |
| Total liabilities | $962,984 | $917,996 | $863,311 | $813,795 | $1.30M | $1.26M | $1.22M | $1.15M |
| Shareholders' equity | -$936,040 | -$881,054 | -$809,207 | -$773,820 | -$1.26M | -$1.18M | -$1.11M | -$1.27M |
| Shares outstanding | 2.92B | 2.92B | 2.92B | 2.74B | 2.30B | 2.30B | 2.21B | 1.78B |
| Cash flow statement | ||||||||
| Operating cash flow | -$442 | -$2,004 | -$8,831 | $1,513 | -$23,225 | -$38,863 | -$92,668 | -$53,002 |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$53,002 |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $0 | $0 | $10,000 | $0 | -$2,644 | $50,000 | $106,800 | $25,000 |
| Depreciation & amortization | $9,051 | $13,039 | $19,726 | $19,727 | $19,726 | $19,727 | $19,726 | $19,727 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.